US Just Started The First Human Trial of a Vaccine For The New Coronavirus – ´´The first human trial to evaluate a candidate vaccine against the new coronavirus has begun in Seattle, US health officials said Monday, raising hopes in the global fight against the disease. But it may be another year to 18 months before it becomes available, once it has passed more trial phases to prove it works and is safe. The vaccine is called mRNA-1273 and was developed by US National Institutes of Health (NIH) scientists and collaborators at biotechnology company Moderna, which is based in Cambridge, Massachusetts. The open-label trial will enroll 45 healthy adult volunteers ages 18 to 55 years over approximately 6 weeks,” the NIH said. “The first participant received the investigational vaccine today. Funding was also provided by the Oslo-based Coalition for Epidemic Preparedness Innovations (CEPI). There are currently no approved vaccines or treatments against the coronavirus disease, known as COVID-19, which has infected more than 175,000 people across the world since it was first identified in central China in late December. It has claimed 7,000 deaths, according to an AFP tally, most in China followed by Italy. “Finding a safe and effective vaccine to prevent infection with SARS-CoV-2 is an urgent public health priority,” said Anthony Fauci, head of infectious diseases at the NIH, using the technical name for the virus that is believed to have originated in bats. This Phase 1 study, launched in record speed, is an important first step toward achieving that goal.” The Seattle trial will study the impact of different doses delivered by intramuscular injection in the upper arm, with participants monitored for side-effects like soreness or fever. Pharmaceuticals and research labs around the world are racing to develop both treatments and vaccines to the new coronavirus.´´

Do the downloads!! Share!! The diffusion of very important information and knowledge is essential for the world progress always!! Thanks!!

  • – > Mestrado – Dissertation – Tabelas, Figuras e Gráficos – Tables, Figures and Graphics´´My´´ Dissertation @ #Innovation #energy #life #health #Countries #Time #Researches #Reference #Graphics #Ages #Age #Mice #People #Person #Mouse #Genetics #PersonalizedMedicine #Diagnosis #Prognosis #Treatment #Disease #UnknownDiseases #Future #VeryEfficientDrugs #VeryEfficientVaccines #VeryEfficientTherapeuticalSubstances #Tests #Laboratories #Investments #Details #HumanLongevity #DNA #Cell #Memory #Physiology #Nanomedicine #Nanotechnology #Biochemistry #NewMedicalDevices #GeneticEngineering #Internet #History #Science #World #times

Pathol Res Pract. 2012 Jul 15;208(7):377-81. doi: 10.1016/j.prp.2012.04.006. Epub 2012 Jun 8.

The influence of physical activity in the progression of experimental lung cancer in mice

Renato Batista Paceli 1Rodrigo Nunes CalCarlos Henrique Ferreira dos SantosJosé Antonio CordeiroCassiano Merussi NeivaKazuo Kawano NagaminePatrícia Maluf Cury


Impact_Fator-wise_Top100Science_Journals

GRUPO_AF1GROUP AFA1 – Aerobic Physical Activity – Atividade Física Aeróbia – ´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto

GRUPO AFAN 1GROUP AFAN1 – Anaerobic Physical ActivityAtividade Física Anaeróbia – ´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto

GRUPO_AF2GROUP AFA2 – Aerobic Physical ActivityAtividade Física Aeróbia – ´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto

GRUPO AFAN 2GROUP AFAN 2 – Anaerobic Physical ActivityAtividade Física Anaeróbia´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto

Slides – mestrado´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto

CARCINÓGENO DMBA EM MODELOS EXPERIMENTAIS

DMBA CARCINOGEN IN EXPERIMENTAL MODELS

Avaliação da influência da atividade física aeróbia e anaeróbia na progressão do câncer de pulmão experimental – Summary – Resumo´´My´´ Dissertation Faculty of Medicine of Sao Jose do Rio Preto

https://pubmed.ncbi.nlm.nih.gov/22683274/

Abstract

Lung cancer is one of the most incident neoplasms in the world, representing the main cause of mortality for cancer. Many epidemiologic studies have suggested that physical activity may reduce the risk of lung cancer, other works evaluate the effectiveness of the use of the physical activity in the suppression, remission and reduction of the recurrence of tumors. The aim of this study was to evaluate the effects of aerobic and anaerobic physical activity in the development and the progression of lung cancer. Lung tumors were induced with a dose of 3mg of urethane/kg, in 67 male Balb – C type mice, divided in three groups: group 1_24 mice treated with urethane and without physical activity; group 2_25 mice with urethane and subjected to aerobic swimming free exercise; group 3_18 mice with urethane, subjected to anaerobic swimming exercise with gradual loading 5-20% of body weight. All the animals were sacrificed after 20 weeks, and lung lesions were analyzed. The median number of lesions (nodules and hyperplasia) was 3.0 for group 1, 2.0 for group 2 and 1.5-3 (p=0.052). When comparing only the presence or absence of lesion, there was a decrease in the number of lesions in group 3 as compared with group 1 (p=0.03) but not in relation to group 2. There were no metastases or other changes in other organs. The anaerobic physical activity, but not aerobic, diminishes the incidence of experimental lung tumors.

https://www.sciencealert.com/us-begins-first-human-trial-of-coronavirus-vaccine

777777777777777777777777777

868658658569

00000

68456854686868

1x

2x

7654754745

85685648546

85468568568

corona-virus.jpg3Fla3Den

1.jpg

main article image
(Tek Image/Science Photo Library/Getty Images)

US Just Started The First Human Trial of a Vaccine For The New Coronavirus

ISSAM AHMED, AFP
16 MARCH 2020

The first human trial to evaluate a candidate vaccine against the new coronavirus has begun in Seattle, US health officials said Monday, raising hopes in the global fight against the disease.

But it may be another year to 18 months before it becomes available, once it has passed more trial phases to prove it works and is safe.

The vaccine is called mRNA-1273 and was developed by US National Institutes of Health (NIH) scientists and collaborators at biotechnology company Moderna, which is based in Cambridge, Massachusetts.

“The open-label trial will enroll 45 healthy adult volunteers ages 18 to 55 years over approximately 6 weeks,” the NIH said. “The first participant received the investigational vaccine today.”

Funding was also provided by the Oslo-based Coalition for Epidemic Preparedness Innovations (CEPI).

There are currently no approved vaccines or treatments against the coronavirus disease, known as COVID-19, which has infected more than 175,000 people across the world since it was first identified in central China in late December.

It has claimed 7,000 deaths, according to an AFP tally, most in China followed by Italy.

“Finding a safe and effective vaccine to prevent infection with SARS-CoV-2 is an urgent public health priority,” said Anthony Fauci, head of infectious diseases at the NIH, using the technical name for the virus that is believed to have originated in bats.

“This Phase 1 study, launched in record speed, is an important first step toward achieving that goal.”

The Seattle trial will study the impact of different doses delivered by intramuscular injection in the upper arm, with participants monitored for side-effects like soreness or fever.

Coronaviruses are spherical and have spikes protruding from their surface, giving them a crown-like appearance. The spike binds to human cells, allowing the virus to gain entry.

The Moderna candidate vaccine carries the genetic information of this spike in a substance called “messenger RNA.”

Injecting human tissue with the spike’s messenger RNA makes it grow inside the body, thereby eliciting an immune response without having actually infected a person with the full-blown virus.

Global race

Pharmaceuticals and research labs around the world are racing to develop both treatments and vaccines to the new coronavirus.

An antiviral treatment called remdesivir, made by US-based Gilead Sciences, is already in the final stages of clinical trials in Asia and doctors in China have reported it has proven effective in fighting the disease.

But only randomized trials allow scientists to know for sure whether it really helps or whether patients would have recovered without it.

Another US pharma called Inovio, which is creating a DNA-based vaccine, has said it will enter clinical trials next month.

Regeneron is trying to isolate coronavirus-fighting antibodies that can be administered intravenously to confer temporary immunity, and hopes to start human trials by summer.

According to the World Health Organization, 80 percent of COVID-19 cases are mild, 14 percent are severe and about five percent result are critical, resulting in severe respiratory illness that causes the lungs to fill with fluid which in turn prevents oxygen from reaching organs.

Patients with mild cases recover in a week or two while severe cases can take six or more weeks. Recent estimates suggest about one percent of all infected people die.

© Agence France-Presse

Learn More

  1. Coronavirus Dx Emergency Use Authorizations Progressing Rapidly Despite Criticism
    Madeleine Johnson, 360Dx, 2020
  2. Infecção pelo vírus Ebola
    Nicholas J. Beeching et al., BMJ Best Practice, 2018

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s